Newsfeeds Archive - Spark Newswire

1 minute read

FDA
News

Scilex Holding Announces Publication Of Trial Results For SP-102 (SEMDEXA) In PAIN Journal; Focuses On Non-Opioid Pain Management Products For Acute And Chronic Pain

June 14, 1:43 PM

The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for the Study of

SCLX

1 minute read

FDA
News

Scilex Holding Company Announces FDA Approval For Commercial Manufacturing Of Gloperba, A Prophylactic Treatment For Gout Flares In Adults, To Launch June 10, 2024

By Benzinga Newsdesk

June 6, 2:57 PM

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 9.2

SCLX

4 minute read

Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Avi Kapoor

May 20, 1:28 PM

Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday’s session after the company priced a $1.7 million…

AKAN

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

May 20, 12:31 PM

Gainers GT Biopharma (NASDAQ:GTBP) shares rose 173.5% to $8.53 during Monday’s regular session. The market value of their…

AIH

1 minute read

Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit

By Benzinga Newsdesk

May 14, 9:03 AM

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute

SCLX

1 minute read

Scilex Provides Information To Stockholders Regarding Manipulative And Naked Short Selling Of Its Common Stock

By Benzinga Newsdesk

May 13, 9:08 AM

SCLX

2 minute read

Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses

By Benzinga Newsdesk

April 16, 9:08 AM

SCLX

3 minute read

Scilex Holding Company Announces Publication In Anesthesiology Journal Of Results From An Investigator-Initiated Research Study Using ZTlido For The Treatment Of Chronic Neck Pain

By Benzinga Newsdesk

February 20, 10:16 AM

The lifetime prevalence of neck pain in the adult population is estimated to range from 14.2% to 71% with a mean of 48.5%.2 There are currently no approved medical treatments for neck pain in the U.S.The study was a

SCLX

2 minute read

Scilex Holding Company Releases Preliminary Unaudited Financial Results For Gross And Net Sales For The Year Ended December 31, 2023; Total Product Gross Sales Were In The Range Of $150M-$155M; Total Product Net Sales Were In The Range Of $46.5M-$52.5M

By Benzinga Newsdesk

January 2, 10:03 AM

SCLX

2 minute read

Scilex Announces Filing Of A New Drug Submission To Health Canada’s Pharmaceutical Drugs Directorate, Bureau Of Cardiology, Allergy And Neurological Sciences For The Approval Of ELYXYB For Acute Treatment Of Migraine With Or Without Aura In Canada

By Happy Mohamed

December 26, 12:01 PM

ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is

SCLX